My SNMMI Overview

My Organizations
My Councils
My Committees

Theranostics Central:
Professional Resources

SNMMI provides a comprehensive range of professional resources for radiopharmaceutical therapy, including clinical practice guidelines, accreditation support, training materials, regulatory updates, and tools to advance safe, effective therapy implementation.

Reimbursement Guidance

Questions and Answers are Available for Each of the Following:

Pluvicto™

Xofigo®

Lutathera®

SPECT/CT

Learn More

Procedure Standards

SNMMI is continually developing new standards and updating existing procedure standards to reflect those elements of the procedure that are most important in obtaining a high-quality examination.

See the Standards

New in JNM

JNM Publishes Procedure Standard/Practice Guideline for Fibroblast Activation Protein PET

 

Radiopharmaceutical Therapy Centers of Excellence

NEW!

SNMMI created the RPTCOE program to ensure patients have reliable access to high quality radiopharmaceutical therapy, well-integrated into their pathway of care, delivered by highly qualified therapy teams, at technically qualified sites, and led by physicians appropriately trained in nuclear medicine acting as the patient’s “nuclear oncologist.”

Learn More 

Appropriate Use Criteria

SNMMI is continually developing new Appropriate Use Criteria (AUC) documents and updating existing AUCs to reflect when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services.

Learn More

Radiopharmaceutical Therapy Registry (RaPTR)

RaPTR stands for RadioPharmaceutical Therapy Registry. RaPTR is comprised of two components—a REDCap database and MIM Cloud. REDCap hosts data on patients including disease and treatment history along with outcome and adverse events relative to radiopharmaceutical therapies. MIM Cloud—used in the RaPTR PLUS registry—hosts de-identified PET, SPECT, and planar scans. Currently, RaPTR modules include 177Lu-dotatate, 177Lu-PSMA-617, and I-131 (for thyroid cancer) therapies.

View Registry

Dosimetry

SNMMI has a variety of resources for personalized radiopharmaceutical therapy dosimetry. Visit the MIRD webpage to access their suite of dosimetry tools, MIRDsoft.

Learn More

Advocacy for Theranostics

SNMMI champions policies and funding for theranostic drugs while educating regulators and legislators to increase awareness and support.

Learn More